HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Endothelin antagonism prevents early EGFR transactivation but not increased matrix metalloproteinase activity in diabetes.

Abstract
Although past studies have demonstrated decreased renal matrix metalloproteinase (MMP) activity in type 1 diabetes and in mesangial cells grown under high glucose conditions, renal MMP expression and activity in type 2 diabetes and the regulation of MMPs by profibrotic factors involved in diabetic renal complications such as endothelin-1 (ET-1) remained unknown. The renal expression and activity of MMPs in type 2 diabetic Goto-Kakizaki (GK) rats treated with vehicle or ET(A) receptor selective antagonist ABT-627 for 4 wk were assessed by gelatin zymography, fluorogenic gelatinase assay, and immunoblotting. In addition, expression and phosphorylation of epidermal growth factor receptor (EGFR) and connective tissue growth factor were evaluated by immunoblotting. Renal sections stained with Masson trichrome were used to investigate kidney structure. MMP-2 activity and protein levels were significantly increased in both cortical and medullary regions in the GK rats. Membrane-bound MMP (MT1-MMP), MMP-9, and fibronectin levels were also increased, and ABT-627 treatment did not have an effect on MMP activity and expression. Histological analysis of kidneys did not reveal any structural changes. Phosphorylation of EGFR was significantly increased in the diabetic animals, and ABT-627 treatment prevented this increase, suggesting ET-1-mediated transactivation of EGFR. These results suggest that there is early upregulation of renal MMPs in the absence of any kidney damage. Although the ET(A) receptor subtype is not involved in the early activation of MMPs in type 2 diabetes, ET-1 contributes to transactivation of growth-promoting and profibrotic EGFR.
AuthorsVera Portik-Dobos, Alex K Harris, Weiwei Song, Jimmie Hutchinson, Maribeth H Johnson, John D Imig, David M Pollock, Adviye Ergul
JournalAmerican journal of physiology. Regulatory, integrative and comparative physiology (Am J Physiol Regul Integr Comp Physiol) Vol. 290 Issue 2 Pg. R435-41 (Feb 2006) ISSN: 0363-6119 [Print] United States
PMID16239374 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Blood Glucose
  • Endothelins
  • Fibronectins
  • Pyrrolidines
  • Egfr protein, rat
  • ErbB Receptors
  • Matrix Metalloproteinase 2
  • Matrix Metalloproteinase 9
  • Atrasentan
Topics
  • Animals
  • Atrasentan
  • Blood Glucose (metabolism)
  • Diabetes Mellitus, Type 2 (enzymology, metabolism)
  • Endothelins (antagonists & inhibitors, metabolism)
  • ErbB Receptors (genetics)
  • Fibronectins (metabolism)
  • Gene Expression Regulation, Enzymologic
  • Kidney (enzymology)
  • Male
  • Matrix Metalloproteinase 2 (metabolism)
  • Matrix Metalloproteinase 9 (metabolism)
  • Phosphorylation
  • Pyrrolidines (pharmacology)
  • Rats
  • Rats, Inbred Strains
  • Transcriptional Activation

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: